[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease

Per Borghammer

Status: Completed

Conditions: Parkinson's Disease

Treatments: Other: [11C]donepezil PET

Study type: Observational

Funder types: Other

Identifiers

NCT02012595

2013-003775-35 (EudraCT Number)

2013-01

Details and patient eligibility

About

AIM: Investigate wether there are differences in the parasympathetic nervous system in Parkinsons patients compared to controls.

MATERIALS AND METHODS: We use the tracer [11C]donepezil to image the parasympathetic nervous system. The Investigators will include 20 Parkinsons patients and 20 healthy controls aged 40-80 in our study. The participants will receive a careful medical examination, including a neurological examination, as part of the inclusion process. The subjects also have an MRI scan of the brain. Then PET/CT scans with [11C]donepezil are conducted - once for the upper abdominal region and once for the head region. For evaluating the function of the parasympathetic nervous system gastric emptying time, heart rate variability and salivary flow will be measured. These measureless will be correlated to the PET findings.

PERSPECTIVES: The study will potentially result in the development of a PET ligand for imaging the parasympathetic nervous system. This will have applications for research in Parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic nervous system is involved

Enrollment: 24 patients

Sex: All

Ages: 40 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age 40-80 years

Exclusion criteria

• dementia,
• psychiatric diseases,
• serious medical illness including any type of previous cancer
• any drug with known interaction with the autonomic nervous system
• metal in the body (because of MRI scan)
• pregnancy or breast feeding (because of radiation due to PET/CT)
• known diseases of the salivary glands, stomach, intestines.
• Prior major surgery to salivary glands, esophagus, stomach.

Trial design

24 participants in 2 patient groups

Parkinson's patients

Description:

Participants with Parkinson's Disease

Treatment:

Other: [11C]donepezil PET

Healthy Controls

Description:

Healthy participants

Treatment:

Other: [11C]donepezil PET